Fatty liver disease (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fatty liver disease" in English language version.

refsWebsite

Global rank English rank

50nih.gov

4^th place

33doi.org

2^nd place

8semanticscholar.org

11^th place

8^th place

3handle.net

102^nd place

76^th place

2worldcat.org

5^th place

2harvard.edu

18^th place

17^th place

2medscape.com

719^th place

636^th place

1archive.org

6^th place

1radathand.com

low place

1theguardian.com

12^th place

11^th place

1eurekalert.org

3,538^th place

3,083^rd place

1creativecommons.org

1,010^th place

612^th place

1vin.com

low place

1animalhouseofchicago.com

low place

1petmd.com

low place

7,501^st place

animalhouseofchicago.com

"Fatty Liver Disease in Birds". Animal House of Chicago. Retrieved 29 December 2020.

archive.org

Reid AE (2006). "Chapter 82: Nonalcoholic Fatty Liver Disease". In Feldman M, Friedman LS, Brandt LJ (eds.). Sleisenger and Fordtran's Gastrointestinal and Liver Disease (8th ed.). Philadelphia: W.B. Saunders Company. ISBN 978-1-4160-0245-1. Retrieved 4 July 2023 – via Internet Archive.

creativecommons.org

Cinque F, Cespiati A, Lombardi R, Costantino A, Maffi G, Alletto F, et al. (January 2022). "Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown". Nutrients. 14 (3): 556. doi:10.3390/nu14030556. ISSN 2072-6643. PMC 8838646. PMID 35276911. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.

doi.org

Singh S, Osna NA, Kharbanda KK (28 September 2017). "Treatment options for alcoholic and non-alcoholic fatty liver disease: A review". World Journal of Gastroenterology. 23 (36): 6549–6570. doi:10.3748/wjg.v23.i36.6549. PMC 5643281. PMID 29085205.
Basra S (2011). "Definition, epidemiology and magnitude of alcoholic hepatitis". World Journal of Hepatology. 3 (5): 108–113. doi:10.4254/wjh.v3.i5.108. PMC 3124876. PMID 21731902.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. (2023). "A multi-society Delphi consensus statement on new fatty liver disease nomenclature". Hepatology. 78 (6): 1966–1986. doi:10.1097/HEP.0000000000000520. hdl:10807/245116. ISSN 0270-9139. PMC 10653297. PMID 37363821. S2CID 259260747.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. (January 2018). "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases". Hepatology. 67 (1): 328–357. doi:10.1002/hep.29367. hdl:1805/14037. PMID 28714183.
Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R (April 2015). "Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies". Clinical Gastroenterology and Hepatology. 13 (4): 643–654.e9. doi:10.1016/j.cgh.2014.04.014. PMC 4208976. PMID 24768810.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. (20 September 2017). "Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention". Nature Reviews Gastroenterology & Hepatology. 15 (1): 11–20. doi:10.1038/nrgastro.2017.109. hdl:2318/1659230. PMID 28930295. S2CID 31345431.
Bellentani S (January 2017). "The epidemiology of non-alcoholic fatty liver disease". Liver International. 37: 81–84. doi:10.1111/liv.13299. PMID 28052624.
Reddy JK, Rao MS (May 2006). "Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation". American Journal of Physiology. Gastrointestinal and Liver Physiology. 290 (5): G852-8. doi:10.1152/ajpgi.00521.2005. PMID 16603729.
Angulo P (18 April 2002). "Nonalcoholic Fatty Liver Disease". New England Journal of Medicine. 346 (16): 1221–1231. doi:10.1056/NEJMra011775. PMID 11961152.
Osman KA, Osman MM, Ahmed MH (January 2007). "Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?". Expert Opinion on Drug Safety. 6 (1): 1–4. doi:10.1517/14740338.6.1.1. PMID 17181445. S2CID 33505288.
Marciano F, Savoia M, Vajro P (February 2016). "Celiac disease-related hepatic injury: Insights into associated conditions and underlying pathomechanisms". Digestive and Liver Disease. 48 (2): 112–9. doi:10.1016/j.dld.2015.11.013. PMID 26711682.
Valenti L, Dongiovanni P, Piperno A, Fracanzani AL, Maggioni M, Rametta R, et al. (October 2006). "Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage". Hepatology. 44 (4): 857–64. doi:10.1002/hep.21329. PMID 17006922. S2CID 26068505.
Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. (July 2005). "The natural history of nonalcoholic fatty liver disease: a population-based cohort study". Gastroenterology. 129 (1): 113–21. doi:10.1053/j.gastro.2005.04.014. PMID 16012941.
Crabb DW, Galli A, Fischer M, You M (August 2004). "Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha". Alcohol. 34 (1): 35–8. doi:10.1016/j.alcohol.2004.07.005. PMID 15670663.
Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R (August 2004). "Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis". Diabetes Care. 27 (8): 2057–66. doi:10.2337/diacare.27.8.2057. PMID 15277442.
Day CP, James OF (April 1998). "Steatohepatitis: a tale of two "hits"?". Gastroenterology. 114 (4): 842–5. doi:10.1016/S0016-5085(98)70599-2. PMID 9547102.
Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM (February 2004). "Pathologic features associated with fibrosis in nonalcoholic fatty liver disease". Human Pathology. 35 (2): 196–9. doi:10.1016/j.humpath.2003.09.018. PMID 14991537.
Zafrani ES (January 2004). "Non-alcoholic fatty liver disease: an emerging pathological spectrum". Virchows Archiv. 444 (1): 3–12. doi:10.1007/s00428-003-0943-7. PMID 14685853. S2CID 7708476.
Adams LA, Angulo P, Lindor KD (29 March 2005). "Nonalcoholic fatty liver disease". Canadian Medical Association Journal. 172 (7): 899–905. doi:10.1503/cmaj.045232. PMC 554876. PMID 15795412.
Peleg N, Issachar A, Sneh-Arbib O, Shlomai A (October 2017). "AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease". Digestive and Liver Disease. 49 (10): 1133–1138. doi:10.1016/j.dld.2017.05.002. PMID 28572039.
Peleg N, Sneh Arbib O, Issachar A, Cohen-Naftaly M, Braun M, Shlomai A (14 August 2018). "Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease". PLOS ONE. 13 (8): e0202393. Bibcode:2018PLoSO..1302393P. doi:10.1371/journal.pone.0202393. PMC 6091950. PMID 30106985.
Singh S, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, et al. (28 August 2015). "Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis". European Radiology. 26 (5): 1431–1440. doi:10.1007/s00330-015-3949-z. PMC 5051267. PMID 26314479.
Benedict M, Zhang X (June 2017). "Non-alcoholic fatty liver disease: An expanded review". World Journal of Hepatology. 9 (16): 715–732. doi:10.4254/wjh.v9.i16.715. PMC 5468341. PMID 28652891.
Buchman AL, Dubin MD, Moukarzel AA, Jenden DJ, Roch M, Rice KM, et al. (November 1995). "Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation". Hepatology. 22 (5): 1399–403. doi:10.1002/hep.1840220510. PMID 7590654. S2CID 20227016.
Buchman AL, Dubin M, Jenden D, Moukarzel A, Roch MH, Rice K, et al. (April 1992). "Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients". Gastroenterology. 102 (4 Pt 1): 1363–70. doi:10.1016/0016-5085(92)70034-9. PMID 1551541.
Buchman AL, Ament ME, Sohel M, Dubin M, Jenden DJ, Roch M, et al. (2016). "Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial". Journal of Parenteral and Enteral Nutrition. 25 (5): 260–8. doi:10.1177/0148607101025005260. PMID 11531217.
Hollenbeck CB (August 2010). "The importance of being choline". Journal of the American Dietetic Association. 110 (8): 1162–5. doi:10.1016/j.jada.2010.05.012. PMID 20656090.
Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, et al. (February 2021). "Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults". Clinical Gastroenterology and Hepatology. 20 (3): e573 – e582. doi:10.1016/j.cgh.2021.02.030. PMID 33618024. S2CID 232018678.
Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. (15 November 2005). "The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease". Annals of Internal Medicine. 143 (10): 722–728. doi:10.7326/0003-4819-143-10-200511150-00009. PMID 16287793. S2CID 22475943.
Cinque F, Cespiati A, Lombardi R, Costantino A, Maffi G, Alletto F, et al. (January 2022). "Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown". Nutrients. 14 (3): 556. doi:10.3390/nu14030556. ISSN 2072-6643. PMC 8838646. PMID 35276911. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Dutta D, Nagendra L, Mohindra R, Bhattacharya S, Joshi A, Kamrul-Hasan A (2024). "Role of Growth Hormone Therapy in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis". Indian Journal of Endocrinology and Metabolism. 28 (4): 336–342. doi:10.4103/ijem.ijem_488_23. PMC 11451958. PMID 39371653.
Kalyesubula M, Mopuri R, Rosov A, Alon T, Edery N, Moallem U, et al. (December 2020). "Hyperglycemia-stimulating diet induces liver steatosis in sheep". Scientific Reports. 10 (1): 12189. Bibcode:2020NatSR..1012189K. doi:10.1038/s41598-020-68909-z. PMC 7376193. PMID 32699301.
Kalyesubula M, Mopuri R, Asiku J, Rosov A, Yosefi S, Edery N, et al. (1 March 2021). "High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition". Disease Models & Mechanisms. 14 (3): dmm048355. doi:10.1242/dmm.048355. PMC 7988776. PMID 33608323.

eurekalert.org

SPINK HEALTH (11 April 2019). "Nonalcoholic fatty liver disease found in large numbers of teenagers and young adults". EurekAlert! (Press release). American Association for the Advancement of Science. Retrieved 4 July 2023.

handle.net

hdl.handle.net

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. (2023). "A multi-society Delphi consensus statement on new fatty liver disease nomenclature". Hepatology. 78 (6): 1966–1986. doi:10.1097/HEP.0000000000000520. hdl:10807/245116. ISSN 0270-9139. PMC 10653297. PMID 37363821. S2CID 259260747.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. (January 2018). "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases". Hepatology. 67 (1): 328–357. doi:10.1002/hep.29367. hdl:1805/14037. PMID 28714183.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. (20 September 2017). "Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention". Nature Reviews Gastroenterology & Hepatology. 15 (1): 11–20. doi:10.1038/nrgastro.2017.109. hdl:2318/1659230. PMID 28930295. S2CID 31345431.

harvard.edu

ui.adsabs.harvard.edu

Peleg N, Sneh Arbib O, Issachar A, Cohen-Naftaly M, Braun M, Shlomai A (14 August 2018). "Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease". PLOS ONE. 13 (8): e0202393. Bibcode:2018PLoSO..1302393P. doi:10.1371/journal.pone.0202393. PMC 6091950. PMID 30106985.
Kalyesubula M, Mopuri R, Rosov A, Alon T, Edery N, Moallem U, et al. (December 2020). "Hyperglycemia-stimulating diet induces liver steatosis in sheep". Scientific Reports. 10 (1): 12189. Bibcode:2020NatSR..1012189K. doi:10.1038/s41598-020-68909-z. PMC 7376193. PMID 32699301.

medscape.com

"A Liver Disease Gets a New Name, Diagnostic Criteria". Medscape. Retrieved 4 September 2023.

emedicine.medscape.com

Fatty Liver at eMedicine

nih.gov

pubmed.ncbi.nlm.nih.gov

Singh S, Osna NA, Kharbanda KK (28 September 2017). "Treatment options for alcoholic and non-alcoholic fatty liver disease: A review". World Journal of Gastroenterology. 23 (36): 6549–6570. doi:10.3748/wjg.v23.i36.6549. PMC 5643281. PMID 29085205.
Antunes C, Azadfard M, Hoilat GJ, Gupta M (2022). "Fatty Liver". StatPearls. StatPearls Publishing. PMID 28723021.
Basra S (2011). "Definition, epidemiology and magnitude of alcoholic hepatitis". World Journal of Hepatology. 3 (5): 108–113. doi:10.4254/wjh.v3.i5.108. PMC 3124876. PMID 21731902.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. (2023). "A multi-society Delphi consensus statement on new fatty liver disease nomenclature". Hepatology. 78 (6): 1966–1986. doi:10.1097/HEP.0000000000000520. hdl:10807/245116. ISSN 0270-9139. PMC 10653297. PMID 37363821. S2CID 259260747.
Iser D, Ryan M (July 2013). "Fatty liver disease—a practical guide for GPs". Australian Family Physician. 42 (7): 444–7. PMID 23826593.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. (January 2018). "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases". Hepatology. 67 (1): 328–357. doi:10.1002/hep.29367. hdl:1805/14037. PMID 28714183.
Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R (April 2015). "Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies". Clinical Gastroenterology and Hepatology. 13 (4): 643–654.e9. doi:10.1016/j.cgh.2014.04.014. PMC 4208976. PMID 24768810.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. (20 September 2017). "Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention". Nature Reviews Gastroenterology & Hepatology. 15 (1): 11–20. doi:10.1038/nrgastro.2017.109. hdl:2318/1659230. PMID 28930295. S2CID 31345431.
Qian Y, Fan JG (May 2005). "Obesity, fatty liver and liver cancer". Hepatobiliary & Pancreatic Diseases International. 4 (2): 173–7. PMID 15908310.
Bellentani S (January 2017). "The epidemiology of non-alcoholic fatty liver disease". Liver International. 37: 81–84. doi:10.1111/liv.13299. PMID 28052624.
Reddy JK, Rao MS (May 2006). "Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation". American Journal of Physiology. Gastrointestinal and Liver Physiology. 290 (5): G852-8. doi:10.1152/ajpgi.00521.2005. PMID 16603729.
Angulo P (18 April 2002). "Nonalcoholic Fatty Liver Disease". New England Journal of Medicine. 346 (16): 1221–1231. doi:10.1056/NEJMra011775. PMID 11961152.
Bayard M, Holt J, Boroughs E (June 2006). "Nonalcoholic fatty liver disease". American Family Physician. 73 (11): 1961–8. PMID 16770927.
Osman KA, Osman MM, Ahmed MH (January 2007). "Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?". Expert Opinion on Drug Safety. 6 (1): 1–4. doi:10.1517/14740338.6.1.1. PMID 17181445. S2CID 33505288.
Marciano F, Savoia M, Vajro P (February 2016). "Celiac disease-related hepatic injury: Insights into associated conditions and underlying pathomechanisms". Digestive and Liver Disease. 48 (2): 112–9. doi:10.1016/j.dld.2015.11.013. PMID 26711682.
Valenti L, Dongiovanni P, Piperno A, Fracanzani AL, Maggioni M, Rametta R, et al. (October 2006). "Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage". Hepatology. 44 (4): 857–64. doi:10.1002/hep.21329. PMID 17006922. S2CID 26068505.
Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. (July 2005). "The natural history of nonalcoholic fatty liver disease: a population-based cohort study". Gastroenterology. 129 (1): 113–21. doi:10.1053/j.gastro.2005.04.014. PMID 16012941.
Crabb DW, Galli A, Fischer M, You M (August 2004). "Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha". Alcohol. 34 (1): 35–8. doi:10.1016/j.alcohol.2004.07.005. PMID 15670663.
Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R (August 2004). "Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis". Diabetes Care. 27 (8): 2057–66. doi:10.2337/diacare.27.8.2057. PMID 15277442.
Day CP, James OF (April 1998). "Steatohepatitis: a tale of two "hits"?". Gastroenterology. 114 (4): 842–5. doi:10.1016/S0016-5085(98)70599-2. PMID 9547102.
Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM (February 2004). "Pathologic features associated with fibrosis in nonalcoholic fatty liver disease". Human Pathology. 35 (2): 196–9. doi:10.1016/j.humpath.2003.09.018. PMID 14991537.
Zafrani ES (January 2004). "Non-alcoholic fatty liver disease: an emerging pathological spectrum". Virchows Archiv. 444 (1): 3–12. doi:10.1007/s00428-003-0943-7. PMID 14685853. S2CID 7708476.
Adams LA, Angulo P, Lindor KD (29 March 2005). "Nonalcoholic fatty liver disease". Canadian Medical Association Journal. 172 (7): 899–905. doi:10.1503/cmaj.045232. PMC 554876. PMID 15795412.
Peleg N, Issachar A, Sneh-Arbib O, Shlomai A (October 2017). "AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease". Digestive and Liver Disease. 49 (10): 1133–1138. doi:10.1016/j.dld.2017.05.002. PMID 28572039.
Peleg N, Sneh Arbib O, Issachar A, Cohen-Naftaly M, Braun M, Shlomai A (14 August 2018). "Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease". PLOS ONE. 13 (8): e0202393. Bibcode:2018PLoSO..1302393P. doi:10.1371/journal.pone.0202393. PMC 6091950. PMID 30106985.
Singh S, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, et al. (28 August 2015). "Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis". European Radiology. 26 (5): 1431–1440. doi:10.1007/s00330-015-3949-z. PMC 5051267. PMID 26314479.
Benedict M, Zhang X (June 2017). "Non-alcoholic fatty liver disease: An expanded review". World Journal of Hepatology. 9 (16): 715–732. doi:10.4254/wjh.v9.i16.715. PMC 5468341. PMID 28652891.
Buchman AL, Dubin MD, Moukarzel AA, Jenden DJ, Roch M, Rice KM, et al. (November 1995). "Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation". Hepatology. 22 (5): 1399–403. doi:10.1002/hep.1840220510. PMID 7590654. S2CID 20227016.
Buchman AL, Dubin M, Jenden D, Moukarzel A, Roch MH, Rice K, et al. (April 1992). "Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients". Gastroenterology. 102 (4 Pt 1): 1363–70. doi:10.1016/0016-5085(92)70034-9. PMID 1551541.
Buchman AL, Ament ME, Sohel M, Dubin M, Jenden DJ, Roch M, et al. (2016). "Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial". Journal of Parenteral and Enteral Nutrition. 25 (5): 260–8. doi:10.1177/0148607101025005260. PMID 11531217.
Hollenbeck CB (August 2010). "The importance of being choline". Journal of the American Dietetic Association. 110 (8): 1162–5. doi:10.1016/j.jada.2010.05.012. PMID 20656090.
Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, et al. (February 2021). "Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults". Clinical Gastroenterology and Hepatology. 20 (3): e573 – e582. doi:10.1016/j.cgh.2021.02.030. PMID 33618024. S2CID 232018678.
Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. (15 November 2005). "The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease". Annals of Internal Medicine. 143 (10): 722–728. doi:10.7326/0003-4819-143-10-200511150-00009. PMID 16287793. S2CID 22475943.
Cinque F, Cespiati A, Lombardi R, Costantino A, Maffi G, Alletto F, et al. (January 2022). "Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown". Nutrients. 14 (3): 556. doi:10.3390/nu14030556. ISSN 2072-6643. PMC 8838646. PMID 35276911. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Dutta D, Nagendra L, Mohindra R, Bhattacharya S, Joshi A, Kamrul-Hasan A (2024). "Role of Growth Hormone Therapy in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis". Indian Journal of Endocrinology and Metabolism. 28 (4): 336–342. doi:10.4103/ijem.ijem_488_23. PMC 11451958. PMID 39371653.
Kalyesubula M, Mopuri R, Rosov A, Alon T, Edery N, Moallem U, et al. (December 2020). "Hyperglycemia-stimulating diet induces liver steatosis in sheep". Scientific Reports. 10 (1): 12189. Bibcode:2020NatSR..1012189K. doi:10.1038/s41598-020-68909-z. PMC 7376193. PMID 32699301.
Kalyesubula M, Mopuri R, Asiku J, Rosov A, Yosefi S, Edery N, et al. (1 March 2021). "High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition". Disease Models & Mechanisms. 14 (3): dmm048355. doi:10.1242/dmm.048355. PMC 7988776. PMID 33608323.

ncbi.nlm.nih.gov

Singh S, Osna NA, Kharbanda KK (28 September 2017). "Treatment options for alcoholic and non-alcoholic fatty liver disease: A review". World Journal of Gastroenterology. 23 (36): 6549–6570. doi:10.3748/wjg.v23.i36.6549. PMC 5643281. PMID 29085205.
Basra S (2011). "Definition, epidemiology and magnitude of alcoholic hepatitis". World Journal of Hepatology. 3 (5): 108–113. doi:10.4254/wjh.v3.i5.108. PMC 3124876. PMID 21731902.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. (2023). "A multi-society Delphi consensus statement on new fatty liver disease nomenclature". Hepatology. 78 (6): 1966–1986. doi:10.1097/HEP.0000000000000520. hdl:10807/245116. ISSN 0270-9139. PMC 10653297. PMID 37363821. S2CID 259260747.
Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R (April 2015). "Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies". Clinical Gastroenterology and Hepatology. 13 (4): 643–654.e9. doi:10.1016/j.cgh.2014.04.014. PMC 4208976. PMID 24768810.
Adams LA, Angulo P, Lindor KD (29 March 2005). "Nonalcoholic fatty liver disease". Canadian Medical Association Journal. 172 (7): 899–905. doi:10.1503/cmaj.045232. PMC 554876. PMID 15795412.
Peleg N, Sneh Arbib O, Issachar A, Cohen-Naftaly M, Braun M, Shlomai A (14 August 2018). "Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease". PLOS ONE. 13 (8): e0202393. Bibcode:2018PLoSO..1302393P. doi:10.1371/journal.pone.0202393. PMC 6091950. PMID 30106985.
Singh S, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, et al. (28 August 2015). "Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis". European Radiology. 26 (5): 1431–1440. doi:10.1007/s00330-015-3949-z. PMC 5051267. PMID 26314479.
Benedict M, Zhang X (June 2017). "Non-alcoholic fatty liver disease: An expanded review". World Journal of Hepatology. 9 (16): 715–732. doi:10.4254/wjh.v9.i16.715. PMC 5468341. PMID 28652891.
Cinque F, Cespiati A, Lombardi R, Costantino A, Maffi G, Alletto F, et al. (January 2022). "Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown". Nutrients. 14 (3): 556. doi:10.3390/nu14030556. ISSN 2072-6643. PMC 8838646. PMID 35276911. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Dutta D, Nagendra L, Mohindra R, Bhattacharya S, Joshi A, Kamrul-Hasan A (2024). "Role of Growth Hormone Therapy in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis". Indian Journal of Endocrinology and Metabolism. 28 (4): 336–342. doi:10.4103/ijem.ijem_488_23. PMC 11451958. PMID 39371653.
Kalyesubula M, Mopuri R, Rosov A, Alon T, Edery N, Moallem U, et al. (December 2020). "Hyperglycemia-stimulating diet induces liver steatosis in sheep". Scientific Reports. 10 (1): 12189. Bibcode:2020NatSR..1012189K. doi:10.1038/s41598-020-68909-z. PMC 7376193. PMID 32699301.
Kalyesubula M, Mopuri R, Asiku J, Rosov A, Yosefi S, Edery N, et al. (1 March 2021). "High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition". Disease Models & Mechanisms. 14 (3): dmm048355. doi:10.1242/dmm.048355. PMC 7988776. PMID 33608323.

niddk.nih.gov

"Nonalcoholic Fatty Liver Disease & NASH". National Institute of Diabetes and Digestive and Kidney Diseases. November 2016. Retrieved 7 November 2018.

petmd.com

"Fatty Liver Disease in Cats". PetMD. Retrieved 29 December 2020.

radathand.com

"Liver Steatosis Calculator & Report Generator (CT & MRI)". Rad At Hand. 11 July 2024. Retrieved 26 December 2024.

semanticscholar.org

api.semanticscholar.org

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. (2023). "A multi-society Delphi consensus statement on new fatty liver disease nomenclature". Hepatology. 78 (6): 1966–1986. doi:10.1097/HEP.0000000000000520. hdl:10807/245116. ISSN 0270-9139. PMC 10653297. PMID 37363821. S2CID 259260747.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. (20 September 2017). "Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention". Nature Reviews Gastroenterology & Hepatology. 15 (1): 11–20. doi:10.1038/nrgastro.2017.109. hdl:2318/1659230. PMID 28930295. S2CID 31345431.
Osman KA, Osman MM, Ahmed MH (January 2007). "Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?". Expert Opinion on Drug Safety. 6 (1): 1–4. doi:10.1517/14740338.6.1.1. PMID 17181445. S2CID 33505288.
Valenti L, Dongiovanni P, Piperno A, Fracanzani AL, Maggioni M, Rametta R, et al. (October 2006). "Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage". Hepatology. 44 (4): 857–64. doi:10.1002/hep.21329. PMID 17006922. S2CID 26068505.
Zafrani ES (January 2004). "Non-alcoholic fatty liver disease: an emerging pathological spectrum". Virchows Archiv. 444 (1): 3–12. doi:10.1007/s00428-003-0943-7. PMID 14685853. S2CID 7708476.
Buchman AL, Dubin MD, Moukarzel AA, Jenden DJ, Roch M, Rice KM, et al. (November 1995). "Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation". Hepatology. 22 (5): 1399–403. doi:10.1002/hep.1840220510. PMID 7590654. S2CID 20227016.
Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, et al. (February 2021). "Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults". Clinical Gastroenterology and Hepatology. 20 (3): e573 – e582. doi:10.1016/j.cgh.2021.02.030. PMID 33618024. S2CID 232018678.
Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. (15 November 2005). "The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease". Annals of Internal Medicine. 143 (10): 722–728. doi:10.7326/0003-4819-143-10-200511150-00009. PMID 16287793. S2CID 22475943.

theguardian.com

Sarah Boseley (12 April 2019). "Experts warn of fatty liver disease 'epidemic' in young people". The Guardian. Retrieved 4 July 2023.

vin.com

veterinarypartner.vin.com

Lock B (8 August 2017). "Hepatic Lipidosis (Fatty Liver Disease) in Reptiles". Vin.com. Retrieved 29 December 2020.

worldcat.org

search.worldcat.org

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. (2023). "A multi-society Delphi consensus statement on new fatty liver disease nomenclature". Hepatology. 78 (6): 1966–1986. doi:10.1097/HEP.0000000000000520. hdl:10807/245116. ISSN 0270-9139. PMC 10653297. PMID 37363821. S2CID 259260747.
Cinque F, Cespiati A, Lombardi R, Costantino A, Maffi G, Alletto F, et al. (January 2022). "Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown". Nutrients. 14 (3): 556. doi:10.3390/nu14030556. ISSN 2072-6643. PMC 8838646. PMID 35276911. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.